ArticleMedical sciences (Basel, Switzerland)2026
Beyond Tissue Origin: Rethinking Experimental Model Selection in Rotator Cuff Research.
Article in Medical sciences (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rotator cuff tears are among the most common tendon disorders and a major cause of shoulder pain and functional impairment. Increasing evidence indicates that rotator cuff pathology is a complex biological disease involving inflammation, oxidative stress, hypoxia, apoptosis, cellular senescence, and dysregulated extracellular matrix (ECM) remodeling. Consequently, in vitro studies using rotator cuff-derived cells have become important tools for investigating disease mechanisms and therapeutic targets. Although rotator cuff-derived cells are widely used and generally regarded as physiologically relevant experimental models, their use is limited by restricted tissue availability, inter-donor variability, and the predominance of specimens obtained from torn or degenerative tendons. Commercially available tenocytes offer advantages in accessibility, standardization, reproducibility, and scalability, yet their use in rotator cuff research remains limited because they are not derived from rotator cuff tissue. This Opinion article provides a multifaceted and balanced reappraisal of the view that rotator cuff-derived cells are indispensable for rotator cuff research and explores the potential role of commercially available tenocytes as complementary experimental models. Current cell-based models are discussed in light of the absence of established rotator cuff-specific molecular markers and the growing recognition of tendon cell heterogeneity. This article does not advocate replacing rotator cuff-derived cells. Rather, it proposes that commercially available tenocytes may serve as complementary experimental models for investigating biological processes-including inflammation, oxidative stress, ECM metabolism, and preliminary drug screening-for which tissue-specific biology may not always be required. A stepwise strategy involving screening in commercial tenocytes, validation in rotator cuff-derived cells, and confirmation in tissue, animal, or clinical studies is proposed to balance experimental accessibility with biological relevance. Such an approach may broaden research accessibility while facilitating translational research in rotator cuff disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.